| Company Name | Aiforia Technologies Plc |
| Founded | 2013 |
| Head office | Helsinki, Finland |
| Website | https://www.aiforia.com/ |
| Contact |
Pathology products by Aiforia Technologies Plc
Subspeciality: Uropathology
Modality: Histopathology
Source: Public
Gleason grading, Prostate cancer detection
The Aiforia® Prostate Cancer Biopsy automatically identifies adenocarcinoma and streamlines the Gleason grading process.
Subspeciality: Uropathology
Modality: Histopathology
Source: Vendor
Detection of perineural invasion features
Aiforia® Prostate Cancer PNI detects subtle perineural invasion (PNI) features and identifies tumor involvement around nerves.
Subspeciality: Uropathology
Modality: Histopathology
Source: Vendor
No key features available
Aiforia® Prostate Cancer Gleason 4 Cribriform automatically detects cribriform patterns in Gleason Grade 4 prostate cancer biopsies from whole slide images (WSI). The software aims to reduce diagnostic variability and support pathologists by streamlining subjective and time-consuming assessments.
Subspeciality: Pulmonary pathology
Modality: Histopathology
Source: Vendor
Lung cancer detection
Aiforia® Lung Cancer PD-L1 automatically detects invasive carcinoma and provides standardized, reproducible tumor proportion scoring (TPS). The software aims to support pathologists by reducing subjectivity and time demands in PD-L1 assessment, to improve diagnostic accuracy and efficiency.
Subspeciality: Breast pathology
Modality: Histopathology
Source: Vendor
Breast cancer detection, Breast cancer grading
Aiforia® Breast Cancer Grading automates breast cancer grading from H&E-stained whole slide images (WSI), identifying invasive carcinoma and ductal carcinoma in situ (DCIS). It scores mitotic count, tubular formation, and nuclear pleomorphism in line with the Nottingham Grading System. The aim of the software is to reduce variability and save time.
Subspeciality: Breast pathology
Modality: Histopathology
Source: Vendor
Breast cancer detection, Quantification of ER-positive and negative tumor cells
Aiforia® Breast Cancer ER automatically detects invasive carcinoma and quantifies ER-positive and ER-negative tumor cells in whole slide images (WSI) or selected tissue areas, providing consistent and objective scoring to support breast cancer diagnostics.
Subspeciality: Breast pathology
Modality: Histopathology
Source: Vendor
Breast cancer detection, Quantification of PR-positive and negative tumor cells
Aiforia® Breast Cancer PR automatically detects invasive carcinoma and quantifies PR-positive and PR-negative cells in whole slide images (WSI) or selected tissue regions. The aim of the software is to enhance diagnostic clarity and improve workflow efficiency.
Subspeciality: Breast pathology
Modality: Histopathology
Source: Vendor
Breast cancer detection, HER2 classification
Aiforia® Breast Cancer HER2 detects invasive carcinoma and scores HER2 expression in accordance with CAP guidelines.
Subspeciality: Breast pathology
Modality: Histopathology
Source: Vendor
Breast cancer detection, Quantification of Ki67-positive and negative tumor cells
Aiforia® Breast Cancer Ki-67 automatically detects invasive carcinoma and quantifies Ki-67–positive and negative tumor cells in whole slide images (WSI) or selected tissue regions, reducing variability and enhancing diagnostic efficiency.
Subspeciality: Multiple
Modality: Histopathology
Source: Vendor
Differentiation between macrometastases, micrometastases, and isolated tumor cells, Metastasis detection in lymph nodes (H&E)
Lymph Node Metastasis supports the detection and quantification of metastases of breast cancer, melanoma, and colorectal cancer in lymph nodes from whole slide images.